MicroRNAs as a therapeutic target for cardiovascular diseases

Paras Kumar Mishra, Neetu Tyagi, Munish Kumar, Suresh C. Tyagi

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Introduction Biogenesis of miRNAs and their regulatory mechanisms MiRNAs in cardiovascular diseases MiRNAs in hypertrophy MiRNAs in cardiac fibrosis MiRNAs in arrhythmia MiRNAs in myocardial infarction MiRNAs in heart failure MiRNAs in angiogenesis MiRNAs in cardiomyopathy MiRNAs in antherogenesis Role of Dicer in cardiomyopathy MiRNAs - a new strategy for treatment of cardiovascular diseases MiRNA - an innovative therapeutic approach MiRNAs in stem cell therapy A new candidate in microRNomics Therapeutic challenges and their remedies Mode of delivery of miRNAs Role of microevironment Approaches of miRNAs in cardiovascular therapy Abstract MicroRNAs (miRNAs) are tiny, endogenous, conserved, non-coding RNAs that negatively modulate gene expression by either promoting the degradation of mRNA or down-regulating the protein production by translational repression. They maintain optimal dose of cellular proteins and thus play a crucial role in the regulation of biological functions. Recent discovery of miRNAs in the heart and their differential expressions in pathological conditions provide glimpses of undiscovered regulatory mechanisms underlying cardiovascular diseases. Nearly 50 miRNAs are overexpressed in mouse heart. The implication of several miRNAs in cardiovascular diseases has been well documented such as miRNA-1 in arrhythmia, miRNA-29 in cardiac fibrosis, miRNA-126 in angiogenesis and miRNA-133 in cardiac hypertrophy. Aberrant expression of Dicer (an enzyme required for maturation of all miRNAs) during heart failure indicates its direct involvement in the regulation of cardiac diseases. MiRNAs and Dicer provide a particular layer of network of precise gene regulation in heart and vascular tissues in a spatiotemporal manner suggesting their implications as a powerful intervention tool for therapy. The combined strategy of manipulating miRNAs in stem cells for their target directed differentiation and optimizing the mode of delivery of miRNAs to the desired cells would determine the future potential of miRNAs to treat a disease. This review embodies the recent progress made in microRNomics of cardiovascular diseases and the future of miRNAs as a potential therapeutic target - the putative challenges and the approaches to deal with it.

Original languageEnglish (US)
Pages (from-to)778-789
Number of pages12
JournalJournal of cellular and molecular medicine
Volume13
Issue number4
DOIs
StatePublished - Apr 1 2009

Fingerprint

MicroRNAs
Cardiovascular Diseases
Therapeutics
Cardiomyopathies
Cardiac Arrhythmias
Fibrosis
Stem Cells
Heart Failure
Ribonuclease III
Untranslated RNA
Gene Regulatory Networks
RNA Stability
Cardiomegaly
Cell- and Tissue-Based Therapy
Hypertrophy
Blood Vessels
Heart Diseases
Proteins

Keywords

  • Cardiovascular diseases
  • Dicer
  • Heart failure
  • MicroRNA
  • MicroRNA-based therapy
  • Stem cell

ASJC Scopus subject areas

  • Molecular Medicine
  • Cell Biology

Cite this

MicroRNAs as a therapeutic target for cardiovascular diseases. / Mishra, Paras Kumar; Tyagi, Neetu; Kumar, Munish; Tyagi, Suresh C.

In: Journal of cellular and molecular medicine, Vol. 13, No. 4, 01.04.2009, p. 778-789.

Research output: Contribution to journalArticle

Mishra, Paras Kumar ; Tyagi, Neetu ; Kumar, Munish ; Tyagi, Suresh C. / MicroRNAs as a therapeutic target for cardiovascular diseases. In: Journal of cellular and molecular medicine. 2009 ; Vol. 13, No. 4. pp. 778-789.
@article{3439d70ba44d4a68a0b4fd4a50ca5ccf,
title = "MicroRNAs as a therapeutic target for cardiovascular diseases",
abstract = "Introduction Biogenesis of miRNAs and their regulatory mechanisms MiRNAs in cardiovascular diseases MiRNAs in hypertrophy MiRNAs in cardiac fibrosis MiRNAs in arrhythmia MiRNAs in myocardial infarction MiRNAs in heart failure MiRNAs in angiogenesis MiRNAs in cardiomyopathy MiRNAs in antherogenesis Role of Dicer in cardiomyopathy MiRNAs - a new strategy for treatment of cardiovascular diseases MiRNA - an innovative therapeutic approach MiRNAs in stem cell therapy A new candidate in microRNomics Therapeutic challenges and their remedies Mode of delivery of miRNAs Role of microevironment Approaches of miRNAs in cardiovascular therapy Abstract MicroRNAs (miRNAs) are tiny, endogenous, conserved, non-coding RNAs that negatively modulate gene expression by either promoting the degradation of mRNA or down-regulating the protein production by translational repression. They maintain optimal dose of cellular proteins and thus play a crucial role in the regulation of biological functions. Recent discovery of miRNAs in the heart and their differential expressions in pathological conditions provide glimpses of undiscovered regulatory mechanisms underlying cardiovascular diseases. Nearly 50 miRNAs are overexpressed in mouse heart. The implication of several miRNAs in cardiovascular diseases has been well documented such as miRNA-1 in arrhythmia, miRNA-29 in cardiac fibrosis, miRNA-126 in angiogenesis and miRNA-133 in cardiac hypertrophy. Aberrant expression of Dicer (an enzyme required for maturation of all miRNAs) during heart failure indicates its direct involvement in the regulation of cardiac diseases. MiRNAs and Dicer provide a particular layer of network of precise gene regulation in heart and vascular tissues in a spatiotemporal manner suggesting their implications as a powerful intervention tool for therapy. The combined strategy of manipulating miRNAs in stem cells for their target directed differentiation and optimizing the mode of delivery of miRNAs to the desired cells would determine the future potential of miRNAs to treat a disease. This review embodies the recent progress made in microRNomics of cardiovascular diseases and the future of miRNAs as a potential therapeutic target - the putative challenges and the approaches to deal with it.",
keywords = "Cardiovascular diseases, Dicer, Heart failure, MicroRNA, MicroRNA-based therapy, Stem cell",
author = "Mishra, {Paras Kumar} and Neetu Tyagi and Munish Kumar and Tyagi, {Suresh C.}",
year = "2009",
month = "4",
day = "1",
doi = "10.1111/j.1582-4934.2009.00744.x",
language = "English (US)",
volume = "13",
pages = "778--789",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - MicroRNAs as a therapeutic target for cardiovascular diseases

AU - Mishra, Paras Kumar

AU - Tyagi, Neetu

AU - Kumar, Munish

AU - Tyagi, Suresh C.

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Introduction Biogenesis of miRNAs and their regulatory mechanisms MiRNAs in cardiovascular diseases MiRNAs in hypertrophy MiRNAs in cardiac fibrosis MiRNAs in arrhythmia MiRNAs in myocardial infarction MiRNAs in heart failure MiRNAs in angiogenesis MiRNAs in cardiomyopathy MiRNAs in antherogenesis Role of Dicer in cardiomyopathy MiRNAs - a new strategy for treatment of cardiovascular diseases MiRNA - an innovative therapeutic approach MiRNAs in stem cell therapy A new candidate in microRNomics Therapeutic challenges and their remedies Mode of delivery of miRNAs Role of microevironment Approaches of miRNAs in cardiovascular therapy Abstract MicroRNAs (miRNAs) are tiny, endogenous, conserved, non-coding RNAs that negatively modulate gene expression by either promoting the degradation of mRNA or down-regulating the protein production by translational repression. They maintain optimal dose of cellular proteins and thus play a crucial role in the regulation of biological functions. Recent discovery of miRNAs in the heart and their differential expressions in pathological conditions provide glimpses of undiscovered regulatory mechanisms underlying cardiovascular diseases. Nearly 50 miRNAs are overexpressed in mouse heart. The implication of several miRNAs in cardiovascular diseases has been well documented such as miRNA-1 in arrhythmia, miRNA-29 in cardiac fibrosis, miRNA-126 in angiogenesis and miRNA-133 in cardiac hypertrophy. Aberrant expression of Dicer (an enzyme required for maturation of all miRNAs) during heart failure indicates its direct involvement in the regulation of cardiac diseases. MiRNAs and Dicer provide a particular layer of network of precise gene regulation in heart and vascular tissues in a spatiotemporal manner suggesting their implications as a powerful intervention tool for therapy. The combined strategy of manipulating miRNAs in stem cells for their target directed differentiation and optimizing the mode of delivery of miRNAs to the desired cells would determine the future potential of miRNAs to treat a disease. This review embodies the recent progress made in microRNomics of cardiovascular diseases and the future of miRNAs as a potential therapeutic target - the putative challenges and the approaches to deal with it.

AB - Introduction Biogenesis of miRNAs and their regulatory mechanisms MiRNAs in cardiovascular diseases MiRNAs in hypertrophy MiRNAs in cardiac fibrosis MiRNAs in arrhythmia MiRNAs in myocardial infarction MiRNAs in heart failure MiRNAs in angiogenesis MiRNAs in cardiomyopathy MiRNAs in antherogenesis Role of Dicer in cardiomyopathy MiRNAs - a new strategy for treatment of cardiovascular diseases MiRNA - an innovative therapeutic approach MiRNAs in stem cell therapy A new candidate in microRNomics Therapeutic challenges and their remedies Mode of delivery of miRNAs Role of microevironment Approaches of miRNAs in cardiovascular therapy Abstract MicroRNAs (miRNAs) are tiny, endogenous, conserved, non-coding RNAs that negatively modulate gene expression by either promoting the degradation of mRNA or down-regulating the protein production by translational repression. They maintain optimal dose of cellular proteins and thus play a crucial role in the regulation of biological functions. Recent discovery of miRNAs in the heart and their differential expressions in pathological conditions provide glimpses of undiscovered regulatory mechanisms underlying cardiovascular diseases. Nearly 50 miRNAs are overexpressed in mouse heart. The implication of several miRNAs in cardiovascular diseases has been well documented such as miRNA-1 in arrhythmia, miRNA-29 in cardiac fibrosis, miRNA-126 in angiogenesis and miRNA-133 in cardiac hypertrophy. Aberrant expression of Dicer (an enzyme required for maturation of all miRNAs) during heart failure indicates its direct involvement in the regulation of cardiac diseases. MiRNAs and Dicer provide a particular layer of network of precise gene regulation in heart and vascular tissues in a spatiotemporal manner suggesting their implications as a powerful intervention tool for therapy. The combined strategy of manipulating miRNAs in stem cells for their target directed differentiation and optimizing the mode of delivery of miRNAs to the desired cells would determine the future potential of miRNAs to treat a disease. This review embodies the recent progress made in microRNomics of cardiovascular diseases and the future of miRNAs as a potential therapeutic target - the putative challenges and the approaches to deal with it.

KW - Cardiovascular diseases

KW - Dicer

KW - Heart failure

KW - MicroRNA

KW - MicroRNA-based therapy

KW - Stem cell

UR - http://www.scopus.com/inward/record.url?scp=65249156118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249156118&partnerID=8YFLogxK

U2 - 10.1111/j.1582-4934.2009.00744.x

DO - 10.1111/j.1582-4934.2009.00744.x

M3 - Article

C2 - 19320780

AN - SCOPUS:65249156118

VL - 13

SP - 778

EP - 789

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

IS - 4

ER -